Author: DOKI, Tomoyoshi; TAKANO, Tomomi; HOHDATSU, Tsutomu
Title: Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha Document date: 2016_6_4
ID: y0x0quha_25
Snippet: FIP is a fatal inflammatory disease caused by FIPV. Treatment of FIP-induced systemic inflammation with antiinflammatory drugs, such as steroids, has been investigated, but existing anti-inflammatory drugs only transiently improves FIP symptoms, and the survival time and quality of life remain unable to be improved [6] . We previously reported that progression to the FIP was prevented by inhibition of the physiological activity of an inflammatory.....
Document: FIP is a fatal inflammatory disease caused by FIPV. Treatment of FIP-induced systemic inflammation with antiinflammatory drugs, such as steroids, has been investigated, but existing anti-inflammatory drugs only transiently improves FIP symptoms, and the survival time and quality of life remain unable to be improved [6] . We previously reported that progression to the FIP was prevented by inhibition of the physiological activity of an inflammatory cytokine, TNF-alpha. When anti-fTNF-alpha mouse mAb was administered to cats with FIP, their survival time and quality of life were improved [3] . However, administration of mouse mAb to xenogeneic animals may cause adverse reactions. We prepared mouse-feline chimeric mAb (chimeric mAb 2-4) by modifying the mouse anti-fTNF-alpha mAb 2-4 and investigated its fTNF-alpha neutralization activity. In addition, changes in the feline anti-mouse antibody response-inducing ability induced by repeated administration of purified mouse mAb 2-4 and chimeric mAb 2-4 in cats were investigated.
Search related documents:
Co phrase search for related documents- life quality and physiological activity: 1, 2, 3
- life quality and repeat administration: 1
- life quality and response induce: 1, 2
- life quality and survival time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- life quality survival time and mouse mAb administration: 1
- life quality survival time and survival time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- mouse mAb administration and neutralization activity: 1, 2
- mouse mAb administration and response induce: 1
- mouse mAb administration and response induce ability: 1
- mouse mAb administration and survival time: 1, 2
- mouse mAb administration and tnf alpha: 1, 2
- neutralization activity and response induce: 1, 2
- neutralization activity and response induce ability: 1, 2
- neutralization activity and systemic inflammation: 1, 2
- neutralization activity and tnf alpha: 1, 2
- response induce and systemic inflammation: 1
- response induce and tnf alpha: 1, 2
- survival time and tnf alpha: 1
- systemic inflammation and tnf alpha: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Co phrase search for related documents, hyperlinks ordered by date